Getting personal with real-world data at ViVE 2024
At ViVE 2024 in Los Angeles, COTA’s Chief Medical Officer, C.K. Wang, MD will take part in a discussion session called “Data That’s Getting Personal”.
COTA Extends Research Collaboration Agreement With The U.S. Food and Drug Administration
COTA has extended its Research Collaboration Agreement (RCA) with the U.S. Food and Drug Administration (FDA) for an additional three years. This renewed RCA will expand on the objective to explore the applications of real-world data in oncology.
COTA Supports FDA Assessment of Real-World Data through Membership in COVID-19 Evidence Accelerator
Leveraging its past knowledge of real-world evidence applications and learnings, COTA has joined the COVID-19 Evidence Accelerator program, a joint initiative of Friends of Cancer Research (Friends) and the Reagan-Udall Foundation for the Food and Drug Administration. Through this initiative, COTA is delivering findings from its observational, real-world studies using data from over 3,000 patients hospitalized with COVID-19 within the Hackensack Meridian Health network.
COTA Signs Research Collaboration Agreement With The U.S. Food and Drug Administration
Collaboration Aims to Study Variation in Cancer Treatment Patterns by Extracting and Analyzing Real-World Data
